Diabetic ketoacidosis (DKA) is a critical medical emergency, with an estimated annual incidence of 4%–8% among adults with type 1 diabetes (T1D). Up to 80% of children/adolescents <15 years of age present with DKA at the time they are diagnosed with T1D. Although DKA occurs less frequently in individuals with type 2 diabetes, there has been a rise in DKA incidence in this population due to increasing use of sodium–glucose cotransporter 2 inhibitors (SGLT-2i), in which DKA often presents with only moderately elevated glucose. This is referred to as euglycemic DKA (euDKA). While DKA is traditionally linked to T1D, it also constitutes a serious clinical concern in other diabetes phenotypes, such as pregnancy and ketosis-prone diabetes. This article provides an overview of the global burden of DKA, recent advancements in ketone monitoring technologies, and the complexities surrounding diabetes classification. Furthermore, it highlights the development of a continuous dual glucose–ketone sensor and its potential applications in the clinical management of individuals at risk for DKA.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: A pooled analysis of 1108 population-representative studies with 141 million participants. Lancet, 2024; 404(10467):2077–2093; doi: 10.1016/S0140-6736(24)02317-1
GosmanovAR, GosmanovaEO, KitabchiAE. Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. [Updated 2021 May 9]. In: FeingoldKR, AhmedSF, AnawaltB, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Available from:https://www.ncbi.nlm.nih.gov/books/NBK279052/# [Last accessed: March 18, 2025].
5.
Usher-SmithJA, ThompsonM, ErcoleA, WalterFM. Variation between countries in the frequency of diabetic ketoacidosis at first presentation of type 1 diabetes in children: A systematic review. Diabetologia, 2012; 55(11):2878–2894; doi: 10.1007/s00125-012-2690-2
6.
MoraceC, LorelloG, BelloneF, et al.Ketoacidosis and SGLT2 Inhibitors: A Narrative Review. Metabolites, 2024; 14(5):264; doi: 10.3390/metabo14050264
7.
ChowE, ClementS, GargR. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care, 2023; 11(5):e003666; doi: 10.1136/bmjdrc-2023-003666
8.
American Diabetes Association. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025. Diabetes Care, 2025; 48(Supplement_1):S128–S145; doi: 10.2337/dc25-S006
9.
EL-MohandesN, YeeG, BhuttaBS, et al.Pediatric Diabetic Ketoacidosis. [Updated 2023 Aug 21]. In: StatPearls [Internet]. StatPearls Publishing: Treasure Island (FL); 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470282/# [Last accessed: March 18, 2025].
10.
GhimireP, DhamoonAS. Ketoacidosis. [Updated 2022 Aug 8]. In: StatPearls [Internet]. StatPearls Publishing: Treasure Island (FL); 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534848/
11.
KinneyGL, AkturkHK, TaylorDD, et al.Cannabis use is associated with increased risk for diabetic ketoacidosis in adults with type 1 diabetes: Findings from the T1D exchange clinic registry. Diabetes Care, 2020; 43(1):247–249; doi: 10.2337/dc19-0365
12.
AkturkHK, TaylorDD, CamsariUM, et al.Association between cannabis use and risk for diabetic ketoacidosis in adults with type 1 diabetes. JAMA Intern Med, 2019; 179(1):115–118; doi: 10.1001/jamainternmed.2018.5142
13.
FayfmanM, PasquelFJ, UmpierrezGE. Management of hyperglycemic crises: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Med Clin North Am, 2017; 101(3):587–606; doi: 10.1016/j.mcna.2016.12.011
14.
KitabchiAE, UmpierrezGE, MilesJM, FisherJN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care, 2009; 32(7):1335–1343; doi: 10.2337/dc09-903
15.
KitabchiAE, UmpierrezGE, FisherJN, et al.Thirty years of personal experience in hyperglycemic crises: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol Metab, 2008; 93(5):1541–1552; doi: 10.1210/jc.2007-2577
16.
GoguenJ, GilbertJ.. Hyperglycemic Emergencies in Adults. Can J Diabetes.Diabetes Canada Clinical Practice Guidelines Expert Committee. 2018; 42(Suppl 1):S109–S114; doi: 10.1016/j.jcjd.2017.10.013
17.
ShandJAD, MorrowP, BraatvedtG. Mortality after discharge from hospital following an episode of diabetic ketoacidosis. Acta Diabetol, 2022; 59(11):1485–1492; doi: 10.1007/s00592-022-01953-5
18.
McCoyRG, HerrinJ, GalindoRJ, et al.All-cause mortality after hypoglycemic and hyperglycemic emergencies among U.S. adults with diabetes, 2011-2020. Diabetes Res Clin Pract, 2023; 197:110263; doi: 10.1016/j.diabres.2023.110263
19.
GibbFW, TeohWL, GrahamJ, LockmanKA. Risk of death following admission to a UK hospital with diabetic ketoacidosis. Diabetologia, 2016; 59(10):2082–2087; doi: 10.1007/s00125-016-4034-0
20.
HammersenJ, TittelSR, WarnckeK, et al.; DPV Initiative. Previous diabetic ketoacidosis as a risk factor for recurrence in a large prospective contemporary pediatric cohort: Results from the DPV initiative. Pediatr Diabetes, 2021; 22(3):455–462; doi: 10.1111/pedi.13185
21.
PlewaMC, BryantM, King-ThieleR. Euglycemic Diabetic Ketoacidosis. In: StatPearls [Internet]. StatPearls Publishing: Treasure Island (FL); 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554570/
22.
FarsaniSF, BrodoviczK, SoleymanlouN, et al.Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): A systematic literature review. BMJ Open, 2017; 7(7):e016587; doi: 10.1136/bmjopen-2017-016587
23.
KalscheuerH, SeufertJ, LanzingerS, et al.; DPV Initiative. Event rates and risk factors for the development of diabetic ketoacidosis in adult patients with type 1 diabetes: Analysis from the DPV registry based on 46,966 patients. Diabetes Care, 2019; 42(3):e34–e36; doi: 10.2337/dc18-1160
24.
RamphulK, JoynauthJ. An update on the incidence and burden of diabetic ketoacidosis in the U.S. Diabetes Care, 2020; 43(12):e196–e197; doi: 10.2337/dc20-1258
25.
ShakaH, WaniF, El-AmirZ, et al.Comparing patient characteristics and outcomes in type 1 versus type 2 diabetes with diabetic ketoacidosis: A review and a propensity-matched nationwide analysis. J Investig Med, 2021; 69(6):1196–1200; doi: 10.1136/jim-2021-001901
26.
DesaiD, MehtaD, MathiasP, et al.Health care utilization and burden of diabetic ketoacidosis in the U.S. Over the past decade: A nationwide analysis. Diabetes Care, 2018; 41(8):1631–1638; doi: 10.2337/dc17-1379
27.
HurtadoCR, LemorA, VallejoF, et al.Causes and predictors for 30-day re-admissions in adult patients with diabetic ketoacidosis in the United States: A nationwide analysis, 2010-2014. Endocr Pract, 2019; 25(3):242–253; doi: 10.4158/EP-2018-0457
28.
GaffneyA, ChristopherA, KatzA, et al.The incidence of diabetic ketoacidosis during “emerging adulthood” in the USA and Canada: A population-based study. J Gen Intern Med, 2019; 34(7):1244–1250; doi: 10.1007/s11606-019-05006-6
29.
DhatariyaKK, SkedgelC, FordhamR. The cost of treating diabetic ketoacidosis in the UK: A national survey of hospital resource use. Diabet Med, 2017; 34(10):1361–1366; doi: 10.1111/dme.13427
30.
NeuA, WillaschA, EhehaltS, et al.; DIARY Group Baden-Wuerttemberg. Ketoacidosis at onset of type 1 diabetes mellitus in children–frequency and clinical presentation. Pediatr Diabetes, 2003; 4(2):77–81; doi: 10.1034/j.1399-5448.2003.00007.x
31.
CherubiniV, GrimsmannJM, ÅkessonK, et al.Temporal trends in diabetic ketoacidosis at diagnosis of pediatric type 1 diabetes between 2006 and 2016: Results from 13 countries in three conti- nents. Diabetologia, 2020; 63(8):1530–1541; doi: 10.3238/arztebl.m2021.0133
32.
RewersA, KlingensmithG, DavisC, et al.Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: The search for diabetes in youth study. Pediatrics, 2008; 121(5):e1258–e1266; doi: 10.1542/peds.2007-1105
33.
ManuwaldU, SchofferO, HegewaldJ, et al.Ketoacidosis at onset of type 1 diabetes in children up to 14 years of age and the changes over a period of 18 years in Saxony, eastern-Germany: A population based register study. PLoS One, 2019; 14(6):e0218807; doi: 10.1371/journal.pone.0218807
34.
JensenET, StaffordJE, SaydahS, et al.Increase in prevalence of diabetic ketoacidosis at diagnosis among youth with type 1 diabetes: The search for diabetes in youth study. Diabetes Care 1 July 2021; 44(7):1573–1578; doi: 10.2337/dc20-0389
35.
SegererH, WurmM, GrimsmannJM, et al.Diabetic ketoacidosis at manifestation of type 1 diabetes in childhood and adolescence—incidence and risk factors. Dtsch Arztebl Int, 2021; 118(22):367–372; doi: 10.3238/arztebl.m2021.0133
36.
AuzanneauM, RosenbauerJ, WarnckeK, et al.Frequency of ketoacidosis at diagnosis of pediatric type 1 diabetes associated with socioeconomic deprivation and urbanization: Results from the German multicenter DPV registry. Diabetes Care, 2022; 45(8):1807–1813; doi: 10.2337/dc21-2227
37.
VicinanzaA, MessaaouiA, TenoutasseS, DorchyH. Diabetic ketoacidosis in children newly diagnosed with type 1 diabetes mellitus: Role of demographic, clinical, and biochemical features along with genetic and immunological markers as risk factors. A 20-year experience in a tertiary Belgian center. Pediatr Diabetes, 2019; 20(5):584–593; doi: 10.1111/pedi.12864
38.
Usher-SmithJA, ThompsonMJ, SharpSJ, WalterFM. Factors associated with the presence of diabetic ketoacidosis at diagnosis of diabetes in children and young adults: A systematic review. BMJ, 2011; 343:d4092; doi: 10.1136/bmj.d4092
39.
RodbardD. Continuous glucose monitoring: A review of successes, challenges, and opportunities. Diabetes Technol Ther, 2016; 18(Suppl 2):S3–S13; doi: 10.1089/dia.2015.0417
MaahsDM, HermannJM, HolmanN, et al.; National Paediatric Diabetes Audit and Royal College of Paediatrics and Child Health; DPV Initiative; T1D Exchange Clinic Network. Rates of diabetic ketoacidosis: International comparison with 49,859 pediatric patients with type 1 diabe- tes from England, Wales, the U.S., Austria, and Germany. Diabetes Care, 2015; 38(10):1876–1882; doi: 10.2337/dc15-0780
42.
DoyleEA, WeinzimerSA, TamborlaneW. DKA prevention and insulin pumps: Lessons learned from a large pediatric pump practice. Sci Diabetes Self Manag Care, 2022; 48(6):476–482; doi: 10.1177/26350106221125699
43.
VarugheseB, OliverL, LavelleP, et al.EPH179 the economic impact of Diabetic Ketoacidosis (DKA) in people with T1DM at high risk for DKA: A structured literature review. Value in Health, 2022; 25(12):S225; doi: 10.1016/j.jval.2022.09.1100
44.
BenoitSR, ZhangY, GeissLS, et al.Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality — United States, 2000–2014. MMWR Morb Mortal Wkly Rep, 2018; 67(12):362–365. Available from: https://www.cdc.gov/mmwr/volumes/67/wr/mm6712a3.htm [Last accessed:May 25, 2025].
45.
EbrahimiF, KutzA, ChristER, SzinnaiG. Lifetime risk and health-care burden of diabetic ketoacidosis: A population-based study. Front Endocrinol (Lausanne), 2022; 13:940990; doi: 10.3389/fendo.2022.940990
46.
DavisTME, DavisW. Incidence and associates of diabetic ketoacidosis in a community-based cohort: The Fremantle Diabetes Study Phase II. BMJ Open Diabetes Res Care, 2020; 8(1):e000983; doi: 10.1136/bmjdrc-2019-000983
47.
WyshamC, BindalA, Levrat-GuillenF, et al.A systematic literature review on the burden of diabetic ketoacidosis in type 2 diabetes mellitus. Diabetes Obes Metab, 2025; 27(5):2750–2767; doi: 10.1111/dom.16282
48.
KimYG, JeonJY, HanSJ, et al.Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study. Diabetes Obes Metab, 2018; 20(8):1852–1858; doi: 10.1111/dom.13297
49.
FuEL, D’AndreaE, WexlerDJ, et al.Safety of sodium-glucose cotransporter-2 inhibitors in patients with CKD and type 2 diabetes: Population-based US cohort study. Clin J Am Soc Nephrol, 2023; 18(5):592–601; doi: 10.2215/CJN.0000000000000115
50.
LaursenHVB, RøikjerJB, DalJ, JensenMH. Sodium glucose cotransporter-2 inhibitor treatment and the risk of diabetic ketoacidosis in Denmark: A retrospective cohort study of five years of use. Curr Drug Saf, 2021; 16(1):73–81; doi: 10.2174/1574886315666200819114629
51.
MondalS, DasGuptaR, LodhM, et al.Diabetic keto-acidosis in pancreatic diabetes—how is it different from DKA in type 1 or type 2 DM? Int J Diabetes Dev Ctries, 2024; 44(2):278–288; doi: 10.1007/s13410-023-01244-x
52.
SchmittJ, RahmanAF, AshrafA. Concurrent diabetic ketoacidosis with hyperosmolality and/or severe hyperglycemia in youth with type 2 diabetes. Endocrinol Diabetes Metab, 2020; 3(3):e00160; doi: 10.1002/edm2.160
53.
XuY, BaiJ, WangG, et al.Clinical profile of diabetic ketoacidosis in tertiary hospitals in China: A multicentre, clinic-based study. Diabet Med, 2016; 33(2):261–268; doi: 10.1111/dme.12820
54.
AlmazroueiR, AfandiB, AlKindiF, et al.Clinical characteristics and outcomes of diabetic ketoacidosis in patients with type 2 diabetes using SGLT2 inhibitors. Clin Med Insights Endocrinol Diabetes, 2023; 16:11795514231153717; doi: 10.1177/11795514231153717
55.
CharoenpiriyaA, ChailurkitL, OngphiphadhanakulB. Comparisons of biochemical parameters and diabetic ketoacidosis severity in adult patients with type 1 and type 2 diabetes. BMC Endocr Disord, 2022; 22(1):7; doi: 10.1186/s12902-021-00922-3
56.
EledrisiMS, AlkabbaniH, AboawonM, et al.Clinical characteristics and outcomes of care in patients hospitalized with diabetic ketoacidosis. Diabetes Res Clin Pract, 2022; 192:110041; doi: 10.1016/j.diabres.2022.110041
57.
YoCH, LeeMT, GiWT, et al.Prognostic determinants of community-acquired bloodstream infection in type 2 diabetic patients in ED. Am J Emerg Med, 2014; 32(12):1450–1454; doi: 10.1016/j.ajem.2014.08.071
58.
StiermanB, AffulJ, CarrollMD, et al.National Health and Nutrition Examination Survey 2017–March 2020 prepandemic data files—development of files and prevalence estimates for selected health outcomes. National Health Statistics Report. doi:10.15620/cdc:106273 [Last accessed: April 24, 2023].
PetersAL, BuschurEO, BuseJB, et al.Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care, 2015; 38(9):1687–1693; doi: 10.2337/dc15-0843
61.
WoodwardA, WaltersK, DaviesN, et al.Barriers and facilitators of self-management of diabetes amongst people experiencing socioeconomic deprivation: A systematic review and qualitative synthesis. Health Expect, 2024; 27(3):e14070; doi: 10.1111/hex.14070
KovacsA, BunducS, VeresDS, et al.One third of cases of new-onset diabetic ketosis in adults are associated with ketosis-prone type 2 diabetes-A systematic review and meta-analysis. Diabetes Metab Res Rev, 2024; 40(3):e3743; doi: 10.1002/dmrr.3743
64.
MaldonadoMR, OtinianoME, CheemaF, et al.Ketosis-prone diabetes: Dissection of a heterogeneous syndrome using an immunogenetic and metabolic classification. Diabetes, 2003; 52(3):748–762; doi: 10.1210/jc.2003-030180
65.
MisraS, OliverN, DornhorstA. Diabetic ketoacidosis: Not always due to type 1 diabetes. BMJ, 2013; 346:f3501; doi: 10.1136/bmj.f3501
66.
UmpierrezGE, SmileyD, KitabchiAE. Narrative review: Ketosis-prone type 2 diabetes mellitus. Ann Intern Med, 2006; 144(5):350–357; doi: 10.7326/0003-4819-144-5-200603070-00011
67.
PatelSG, HsuJW, JahoorF, et al.Pathogenesis of A−β+ ketosis-prone diabetes. Diabetes, 2013; 62(3):912–922; doi: 10.2337/db12-0624
68.
ChoukemSP, SobngwiE, BoudouP, et al.β- and α-cell dysfunctions in africans with ketosis-prone atypical diabetes during near-normoglycemic remission. Diabetes Care, 2013; 36(1):118–123; doi: 10.2337/dc12-0798
69.
SteenkampDW, AlexanianSM, SternthalE. Approach to the patient with atypical diabetes. CMAJ, 2014; 186(9):678–684; doi: 10.1503/cmaj.130185
70.
MaldonadoMR, OtinianoME, CheemaF, et al.Factors associated with insulin discontinuation in subjects with ketosis-prone diabetes but preserved beta-cell function. Diabet Med, 2005; 22(12):1744–1750; doi: 10.1111/j.1464-5491.2005.01724.x
71.
VellankiP, SmileyDD, StefanovskiD, et al.Randomized controlled study of metformin and Sitagliptin on long-term Normoglycemia remission in African American patients with hyperglycemic crises. Diabetes Care, 2016; 39(11):1948–1955; doi: 10.2337/dc16-0406
72.
MohanM, BaagarKAM, LindowS. Management of diabetic ketoacidosis in pregnancy. The Obstetric & Gynaecologis, 2017; 19(1):55–62; doi: 10.1111/tog.12344
73.
HossainMJ, Al-MamunM, IslamMR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Sci Rep, 2024; 7(3):e2004; doi: 10.1002/hsr2.2004
EshkoliT, BarskiL, FaingelerntY, et al.Diabetic ketoacidosis in pregnancy—case series, pathophysiology, and review of the literature. Eur J Obstet Gynecol Reprod Biol, 2022; 269:41–46; doi: 10.1016/j.ejogrb.2021.12.011
DhanasekaranM, MohanS, EricksonD, et al.Diabetic ketoacidosis in pregnancy: Clinical risk factors, presentation, and outcomes. J Clin Endocrinol Metab, 2022; 107(11):3137–3143; doi: 10.1210/clinem/dgac464
78.
StonerGD. Hyperosmolar Hyperglycemic State. Am Fam Physician, 2017; 96(11):729–736.
79.
UmpierrezGE, DavisGM, ElSayedNA, et al.Hyperglycaemic crises in adults with diabetes: A consensus report. Diabetologia, 2024; 67(8):1455–1479; doi: 10.1007/s00125-024-06183-8
80.
von GeijerL, EkelundM. Ketoacidosis associated with low carbohydrate diet in a non-diabetic lactating woman: a case report. J Med Case Rep, 2015; 9:224; doi: 10.1186/s13256-015-0709-2
81.
CoxK, CocchiMN, SalciccioliJD, et al.Prevalence and significance of lactic acidosis in diabetic ketoacidosis. J Crit Care, 2012; 27(2):132–137; doi: 10.1016/j.jcrc.2011.07.071
82.
MatthewsS, CoatesMM, BukhmanA, et al.Health system capacity to manage diabetic ketoacidosis in nine low-income and lower-middle income countries: A cross-sectional analysis of nationally representative survey data. EClinicalMedicine, 2023; 55:101759; doi: 10.1016/j.eclinm.2022.101759
83.
LarssonCR, JanuszewskiAS, McGrathRT, et al.Suboptimal behaviour and knowledge regarding overnight glycaemia in adults with type 1 diabetes is common. Intern Med J, 2018; 48(9):1080–1086; doi: 10.1111/imj.13798
84.
Albanese-O’NeillA, WuM, MillerKM, et al.; T1D Exchange Clinic Network. Poor adherence to ketone testing in patients with type 1 diabetes. Diabetes Care, 2017; 40(4):e38–e39; doi: 10.2337/dc16-2620
85.
CharleerS, De BlockC, Van HuffelL, et al.Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): A prospective observational real-world cohort study. Diabetes Care, 2020; 43(2):389–397; doi: 10.2337/dc19-1610
86.
RousselR, RivelineJ-P, VicautE, et al.Important drop rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: The RELIEF study. Diabetes Care, 2021; 44(6):1368–1376; doi: 10.2337/dc20-1690 [Last accessed: April 28, 2021].
87.
RivelineJP, RousselR, VicautE, et al.Reduced rate of acute diabetes events with flash glucose monitoring is sustained for 2 years after initiation: Extended outcomes from the RELIEF study. Diabetes Technol Ther, 2022; 24(9):611–618; doi: 10.1089/dia.2022.0085
88.
LyerlaR, Johnson-RabbettB, ShakallyA, et al.Recurrent DKA results in high societal costs—a retrospective study identifying social predictors of recurrence for potential future intervention. Clin Diabetes Endocrinol, 2021; 7(1):13; doi: 10.1186/s40842-021-00127-6
